FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:RFWD2-SRGAP2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: RFWD2-SRGAP2
FusionPDB ID: 73681
FusionGDB2.0 ID: 73681
HgeneTgene
Gene symbol

RFWD2

SRGAP2

Gene ID

64326

23380

Gene nameCOP1 E3 ubiquitin ligaseSLIT-ROBO Rho GTPase activating protein 2
SynonymsCFAP78|FAP78|RFWD2|RNF200ARHGAP34|FNBP2|SRGAP2A|SRGAP3
Cytomap

1q25.1-q25.2

1q32.1

Type of geneprotein-codingprotein-coding
DescriptionE3 ubiquitin-protein ligase COP1E3 ubiquitin-protein ligase RFWD2RING finger protein 200RING-type E3 ubiquitin transferase RFWD2constitutive photomorphogenesis protein 1 homologconstitutive photomorphogenic protein 1putative ubiquitin ligase COP1riSLIT-ROBO Rho GTPase-activating protein 2SLIT-ROBO GAP2formin-binding protein 2rho GTPase-activating protein 34
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000308769, ENST00000367669, 
ENST00000471256, ENST00000414007, 
ENST00000419187, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score17 X 15 X 10=255015 X 15 X 7=1575
# samples 2016
** MAII scorelog2(20/2550*10)=-3.6724253419715
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(16/1575*10)=-3.29920801838728
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: RFWD2 [Title/Abstract] AND SRGAP2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: RFWD2 [Title/Abstract] AND SRGAP2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)RFWD2(176175708)-SRGAP2(206631969), # samples:3
Anticipated loss of major functional domain due to fusion event.RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
RFWD2-SRGAP2 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneRFWD2

GO:0010212

response to ionizing radiation

19805145

TgeneSRGAP2

GO:0043547

positive regulation of GTPase activity

21148482

TgeneSRGAP2

GO:0046847

filopodium assembly

22559944

TgeneSRGAP2

GO:0051014

actin filament severing

21148482

TgeneSRGAP2

GO:0060996

dendritic spine development

22559944

TgeneSRGAP2

GO:2001223

negative regulation of neuron migration

22559944



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:176175708/chr1:206631969)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across RFWD2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SRGAP2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000367669RFWD2chr1176175708-ENST00000419187SRGAP2chr1206631969+12179225151216234
ENST00000308769RFWD2chr1176175708-ENST00000419187SRGAP2chr1206631969+7024070701234

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000367669ENST00000419187RFWD2chr1176175708-SRGAP2chr1206631969+0.55205950.44794053
ENST00000308769ENST00000419187RFWD2chr1176175708-SRGAP2chr1206631969+0.210384030.789616

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for RFWD2-SRGAP2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
RFWD2chr1176175708SRGAP2chr1206631969407136INSYEDKSNDFVWQRKRPESGSIRKT
RFWD2chr1176175708SRGAP2chr1206631969922136INSYEDKSNDFVWQRKRPESGSIRKT

Top

Potential FusionNeoAntigen Information of RFWD2-SRGAP2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RFWD2-SRGAP2_176175708_206631969.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:11KSNDFVWQR0.99450.643615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:03KSNDFVWQR0.99450.643615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:09KSNDFVWQR0.99450.643615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A30:08KSNDFVWQR0.97070.7922615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A31:02KSNDFVWQR0.94310.6017615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A30:08KSNDFVWQRK0.99210.7497616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:03KSNDFVWQRK0.96130.5619616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:11KSNDFVWQRK0.96130.5619616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:09KSNDFVWQRK0.96130.5619616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A31:02KSNDFVWQRKR0.97310.6605617
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:09KSNDFVWQRKR0.970.681617
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:03KSNDFVWQRKR0.970.681617
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:11KSNDFVWQRKR0.970.681617
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A31:01KSNDFVWQR0.99490.5691615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A31:01KSNDFVWQRKR0.97780.6144617
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:01KSNDFVWQR0.99450.643615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A30:01KSNDFVWQR0.97490.9075615
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A30:01KSNDFVWQRK0.99230.8702616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:01KSNDFVWQRK0.96130.5619616
RFWD2-SRGAP2chr1176175708chr1206631969407HLA-A74:01KSNDFVWQRKR0.970.681617

Top

Potential FusionNeoAntigen Information of RFWD2-SRGAP2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RFWD2-SRGAP2_176175708_206631969.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0801SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0801KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0803SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0805SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0805KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0808SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0811SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0814SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0816SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0816KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0818SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0818KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0823SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0826SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0826KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0827SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0833SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0835SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0836SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0837SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0837KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0838SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0839SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0839KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0840SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0840KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-0840DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1111SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1111KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1114SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1119SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1120SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1131SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1168SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1169SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1172SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1173SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1182SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1186SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1193SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1302SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1303SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1303KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1303DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-13101SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-13101KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-13101DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1310SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1310KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1310DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1312SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1312KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1312DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1313SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1313KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1316SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1321SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1321KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1321DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1321NDFVWQRKRPESGSI823
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1323SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1329SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1330SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1330KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1330DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1333SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1333KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1334SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1336SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1336KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1338SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1338KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1338DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1338NDFVWQRKRPESGSI823
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1339SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1341SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1349SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1349KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1349DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1355SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1355KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1363SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1363KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1365SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1365KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1365DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1365NDFVWQRKRPESGSI823
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1366SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1366KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1366DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1373SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1374SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1382SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1385SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1388SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1388KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1388DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1390SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1390KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1390DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1395SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1395KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1395DKSNDFVWQRKRPES520
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1397SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1399SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1413SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1422SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1422KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1425SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1425KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1453SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1453KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1463SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1463KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1469SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1469KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1485SNDFVWQRKRPESGS722
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1485KSNDFVWQRKRPESG621
RFWD2-SRGAP2chr1176175708chr1206631969407DRB1-1485DKSNDFVWQRKRPES520

Top

Fusion breakpoint peptide structures of RFWD2-SRGAP2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4603KSNDFVWQRKRPESRFWD2SRGAP2chr1176175708chr1206631969407

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RFWD2-SRGAP2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4603KSNDFVWQRKRPES-5.97758-6.09098
HLA-B14:023BVN4603KSNDFVWQRKRPES-5.15013-6.18543
HLA-B52:013W394603KSNDFVWQRKRPES-6.29935-6.41275
HLA-B52:013W394603KSNDFVWQRKRPES-6.07479-7.11009
HLA-A24:025HGA4603KSNDFVWQRKRPES-7.25246-8.28776
HLA-A24:025HGA4603KSNDFVWQRKRPES-6.23064-6.34404
HLA-B44:053DX84603KSNDFVWQRKRPES-4.66421-5.69951
HLA-B44:053DX84603KSNDFVWQRKRPES-4.52141-4.63481
HLA-A02:016TDR4603KSNDFVWQRKRPES-7.72945-7.84285

Top

Vaccine Design for the FusionNeoAntigens of RFWD2-SRGAP2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
RFWD2-SRGAP2chr1176175708chr1206631969615KSNDFVWQRCAAAAGCAACGACTTCGTATGGCAAAG
RFWD2-SRGAP2chr1176175708chr1206631969616KSNDFVWQRKCAAAAGCAACGACTTCGTATGGCAAAGGAA
RFWD2-SRGAP2chr1176175708chr1206631969617KSNDFVWQRKRCAAAAGCAACGACTTCGTATGGCAAAGGAAGCG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
RFWD2-SRGAP2chr1176175708chr1206631969520DKSNDFVWQRKRPESGGACAAAAGCAACGACTTCGTATGGCAAAGGAAGCGTCCAGAATC
RFWD2-SRGAP2chr1176175708chr1206631969621KSNDFVWQRKRPESGCAAAAGCAACGACTTCGTATGGCAAAGGAAGCGTCCAGAATCTGG
RFWD2-SRGAP2chr1176175708chr1206631969722SNDFVWQRKRPESGSAAGCAACGACTTCGTATGGCAAAGGAAGCGTCCAGAATCTGGGAG
RFWD2-SRGAP2chr1176175708chr1206631969823NDFVWQRKRPESGSICAACGACTTCGTATGGCAAAGGAAGCGTCCAGAATCTGGGAGCAT

Top

Information of the samples that have these potential fusion neoantigens of RFWD2-SRGAP2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCARFWD2-SRGAP2chr1176175708ENST00000308769chr1206631969ENST00000419187TCGA-AN-A0XW-01A

Top

Potential target of CAR-T therapy development for RFWD2-SRGAP2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to RFWD2-SRGAP2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to RFWD2-SRGAP2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource